Brain drug levels measured in healthy volunteers
NCT ID NCT02362516
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested the drug Iclepertin (BI 425809) in 25 healthy men to see how much of it reaches the brain and how it affects certain brain chemicals. Participants took multiple doses of the tablet, and researchers measured drug levels in blood and spinal fluid. The main goals were to understand the drug's safety and how it behaves in the body, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 425809 (Iclepertin) tablet
- What this could lead to
- If successful, this could help determine the right dose for future studies of Iclepertin in conditions like Alzheimer's or schizophrenia.
- What could go wrong
- This is a very early Phase 1 study in only 25 healthy men, so it cannot prove the drug works for any disease. Side effects are possible but not yet well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
1346.3.32001 Boehringer Ingelheim Investigational Site
Antwerp, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test